ArticleDiving and hyperbaric medicine2025
Longitudinal study of changes in pulmonary function among inside attendants of hyperbaric oxygen therapy.
Article in Diving and hyperbaric medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hyperbaric oxygen therapy (HBOT) administers 100% oxygen in a pressurised chamber at pressures above 1 atmosphere absolute. Inside hyperbaric personnel accompany patients during sessions and breathe compressed air, exposing them to risks like decompression illness and respiratory changes. This study investigated whether hyperbaric exposure affects the long-term lung function of inside hyperbaric personnel. Methods: An analysis was conducted on spirometry data from 14 personnel working between 2012 and 2023. Lung function tests measured forced vital capacity (FVC), forced expiratory volume in one second (FEV1), mid breath forced expiratory flow (FEF25-75), and peak expiratory flow (PEF) before and after hyperbaric exposure. Participants were categorised based on age, body mass index, number of HBOT sessions, and duration of employment. Results: No clinically or statistically significant differences were found in FVC, FEV1, or PEF measurements before and after hyperbaric exposures (P > 0.05). However, FEF25-75, an indicator of small airway function, showed a (mean) 16% reduction in personnel with more than 150 HBOT sessions (P = 0.038). A post-hoc analysis confirmed a significant difference in FEF25-75 between personnel with fewer than 74 sessions and those with 150 or more sessions (P = 0.015). No clinically significant symptoms such as dyspnoea were reported during the study period. Conclusions: The FEF25-75 reduction, without changes in FEV1, FVC, or PEF, could be due to improper performance of the FVC manoeuvre. Maintaining pulmonary health in inside hyperbaric personnel is essential, emphasising the importance of accurate FVC execution in assessments. Further studies are recommended to explore the long-term implications of these findings and the effects of repeated hyperbaric exposure on respiratory health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.